Our assessment of TCGA data for immunohistochemistry-based breast cancer subtype classification revealed that EPHB6 is also significantly downregulated in patient samples, representing very heterogeneous and aggressive tumours of the TNBC group (Figure 1C). This evidence concerns the gene EPHB6 and breast carcinoma.